Clinical trials showed that NeuroAiD™ helps in stroke recovery
NeuroAiD™ doubles chances of achieving independence.
Trials on 605 subjects, recruited within 2 weeks to 6 months after an ischemic stroke, demonstrated that patients on NeuroAiD™ have 2.4 more changes of achieving independence* after 1 month of treatment (p=0.007). Independence for a stroke victim is the ability to walk, think and live decently after his recovery.
*Independence is defined as being able to take care of oneself and speak freely.
NeuroAiD™ improves activities of daily living.
A double-blind, placebo-control clinical trial on 80 subjects showed better improvement in ability to perform activities of daily living at 3 months among NeuroAiD™ treated patients as compared to controls (Barthel Index improvement of 36 vs 29 points; p<0.001).
Improving Motor Recovery
A study of 150 subjects recruited between 1 week and 3 months after stroke onset received 3 months of treatment. Motor recovery was assessed by Fugl-Meyer motor assessment scale (maximum score 100 points) every month for 3 months. This study showed that the motor recovery of patients on NeuroAiD™ was significantly much more than patients on placebo, and this difference was seen as early as 4 weeks from start of treatment and persists up to 3 months..
Trials on 605 subjects recruited within 2 weeks and 6 months post ischemic stroke showed statistically significant improvement in upper limb (p=0.006) and distal lower limb paralysis* (p=0.02) after 1 month of treatment with NeuroAiD™ compared to the control group.
*The recovery of paralysis was measured on a normalized 0-5 points scale before and after treatment.
Effects on other brain functions
NeuroAiD™ supports recovery of visual deficits
A study of 40 patients with pure homonymous hemianopsia from ischemic stroke, recruited within one week of onset and treated with either NeuroAiD™ or piracetam for 3 months, showed that patients on NeuroAiD™ gained back more of their visual field at 3 months compared to control.
A case series published in European Neurology reported 10 cases of patients, from Mount Alvernia Hospital in Singapore, who received 2 to 3 months treatment of NeuroAiD™ after a stroke. Treatment was initiated between one week and six months post-stroke and given as an add-on medication.
The cases were a mixture of anterior and posterior circulation infarction with motor, sensory, balance,vision, and/or speech deficits.
All cases reported improvements:
- 6 cases of full recovery
- 2 cases of good recovery
- 1 case of moderate recovery
- 1 case of only minor recovery
Significant improvements were recorded in speech and visual functions, aside from motor and balance. Remarkably, three patients who started NeuroAiD™ treatment at a later stage of stroke recovery (i.e. 1 to 6 months after the stroke and recovery has reached a plateau) experienced significant recovery.